RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by National Cancer Center / Cancer Hospital, CAMS; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)National Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06839560, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Patients with metastatic HER2-negative breast cancer brain metastasis, with clear clinical documentation; specific criteria refer to the guidelines of the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP).

    Inclusion criterion 2

  3. Previous treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or targeted drugs acting on another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX40, CD137).

    Exclusion criterion 6

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, assessed within 10 days before the start of study treatment.

    Inclusion criterion 9

  5. Known history of another invasive malignancy that is progressing or requires active treatment within the past 5 years. (Subjects with a history of cutaneous basal cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ of the breast treated with curative intent, or in situ cervical cancer are not excluded.)

    Exclusion criterion 5

    Known history of human immunodeficiency virus (HIV) infection.

    Exclusion criterion 15

    Known history of hepatitis B (defined as positive hepatitis B surface antigen [HBsAg]) or known active hepatitis C virus infection (defined as detectable HCV RNA [qualitative]).

    Exclusion criterion 16

  6. Female patients are not pregnant, not breastfeeding, and agree to use necessary contraceptive measures.

    Inclusion criterion 14

    Positive urine pregnancy test within 72 hours before the first dose of study treatment.

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06839560, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Males or females who are at least 18 years of age on the day of signing the informed consent form.
  • Patients with metastatic HER2-negative breast cancer brain metastasis, with clear clinical documentation; specific criteria refer to the guidelines of the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP).
  • Patients who have received no more than one line of chemotherapy during the metastatic stage of breast cancer.
  • Patients with brain metastasis should not require immediate local therapy during the trial and meet at least one of the following criteria:
  • The patient has not previously received intracranial radiotherapy.
  • The patient has not previously undergone surgery for intracranial metastases; if surgery was performed, the surgical lesion is not the target for the planned radiotherapy, or it is the target lesion and has recurred after surgery.
  • The patient must have at least one measurable intracranial lesion, with the longest diameter baseline accurately measurable by magnetic resonance imaging (MRI) as ≥10 mm and suitable for precise repeated measurement according to RECIST 1.1 in combination with RANO criteria. Measurable extracranial lesions are not required.
  • Patients with suspected or confirmed leptomeningeal metastasis should be excluded.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, assessed within 10 days before the start of study treatment.
  • Patients may have previously received anthracycline (e.g., doxorubicin, epirubicin) and/or taxane (e.g., paclitaxel, docetaxel) therapy, specifically including:
  • Before breast cancer recurrence, the patient received anthracycline and/or taxane during adjuvant or neoadjuvant treatment.
  • The patient experienced treatment failure during or after anthracycline and/or taxane-based chemotherapy.
  • In the judgment of the investigator, the patient is not suitable for anthracycline and/or taxane-based chemotherapy as a first-line treatment regimen.
  • Female patients are not pregnant, not breastfeeding, and agree to use necessary contraceptive measures.
  • The patient is able to sign the informed consent form to participate in the study.
  • The patient has adequate organ function, as detailed in Table 1 of the study protocol; all screening laboratory tests should be completed within 10 days before the start of study treatment.

Exclusion Criteria:

  • The subject has leptomeningeal metastasis.
  • If the patient has concurrent brain metastasis, the neurological symptoms are too severe to cooperate with radiotherapy.
  • Malabsorption syndrome, or the disease significantly affects gastrointestinal function; or after subtotal gastrectomy, or after proximal small bowel resection, which may affect the absorption of oral metronomic chemotherapy agents.
  • The subject has dysphagia or is unable to swallow tablets.
  • Known history of another invasive malignancy that is progressing or requires active treatment within the past 5 years. (Subjects with a history of cutaneous basal cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ of the breast treated with curative intent, or in situ cervical cancer are not excluded.)
  • Previous treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or targeted drugs acting on another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX40, CD137).
  • Diagnosis of immunodeficiency or receiving long-term systemic corticosteroid therapy (daily dose exceeding 10 mg prednisone equivalent) or any form of immunosuppressive therapy within 7 days before the first dose of study treatment.
  • Active autoimmune disease requiring systemic treatment within the past 2 years (e.g., use of disease-modifying drugs, corticosteroids, or immunosuppressive agents).
  • History of pneumonia requiring steroid treatment (non-infectious) or current pneumonia.
  • Positive urine pregnancy test within 72 hours before the first dose of study treatment.
  • Active infection requiring systemic treatment.
  • Known history of active tuberculosis.
  • Echocardiogram performed at screening confirms left ventricular ejection fraction (LVEF) <50% or below the institutional lower limit of normal.
  • Other significant cardiac disease, such as: myocardial infarction, acute coronary syndrome, or history of coronary artery angioplasty/stent placement/bypass surgery within the past 6 months; New York Heart Association (NYHA) Class II-IV congestive heart failure (CHF) or history of NYHA Class III or IV CHF.
  • Known history of human immunodeficiency virus (HIV) infection.
  • Known history of hepatitis B (defined as positive hepatitis B surface antigen [HBsAg]) or known active hepatitis C virus infection (defined as detectable HCV RNA [qualitative]).

Quoted from ClinicalTrials.gov, NCT06839560, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06839560, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06839560